Clinical trials: Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
This pilot study has been designed to investigate the safety of pembrolizumab treatment for disease relapse following allogeneic stem cell transplant (alloSCT).
- Conditions
- Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02981914
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
This phase II trial studies how well combination chemotherapy with or without rituximab works in treating participants with stage III-IV classic Hodgkin lymphoma.
- Conditions
- Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Trial name
- NCT00654732
- Testing
- Bleomycin, Dacarbazine, Doxorubicin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin's Disease
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and…
- Trial name
- CheckMate 812 (NCT03138499)
- Testing
- Nivolumab, Brentuximab vedotin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Trial name
- NCT03907488
- Testing
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography
- Where
- 728 sites in United States, Canada and 1 more
- Volunteers
- 994 people
- Sponsor
- National Cancer Institute (NCI)
Classical Hodgkin Lymphoma
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation.
- Trial name
- KEYNOTE-C11 (NCT05008224)
- Testing
- Pembrolizumab, Doxorubicin, Vinblastine
- Where
- 48 sites in United States, Australia and 9 more
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
This phase II trial studies how well combination chemotherapy with or without bortezomib works in treating patients with classical Hodgkin lymphoma that has come back or does not respond to prior treatment.
- Trial name
- NCT00967369
- Testing
- Bortezomib, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin's Lymphoma
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Objectives: Primary objective: Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination Randomized Phase-II: To estimate the complete…
- Trial name
- NCT01169636
- Testing
- Panobinostat, Ifosfamide, Mesna
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine, bendamustine, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or…
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT03739619
- Testing
- Bendamustine, Gemcitabine, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA…
- Conditions
- Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma
- Trial name
- NCT02166463
- Testing
- Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide
- Where
- 199 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Lymphoma
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase II trial studies how well umbralisib and pembrolizumab work in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03776864
- Testing
- Pembrolizumab, Umbralisib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
This phase I trial studies the side effects and the best dose of crizotinib when given together with combination chemotherapy in treating younger patients with solid tumors or anaplastic large cell lymphoma that has returned or…
- Conditions
- Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
- Trial name
- NCT01606878
- Testing
- Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride
- Where
- 23 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Children's Oncology Group
Lymphoma
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00369681
- Testing
- Bleomycin, Rituximab, Dacarbazine
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
This is a study of pembrolizumab (MK-3475) for participants with relapsed/refractory classical Hodgkin Lymphoma (RRcHL) who: 1) have failed to achieve a response or progressed after autologous stem cell transplant (auto-SCT) and…
- Trial name
- NCT02453594
- Testing
- pembrolizumab
- Volunteers
- 211 people
- Sponsor
- Merck Sharp & Dohme LLC
Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant.
- Conditions
- Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin
- Trial name
- NCT01660607
- Testing
- CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Stanford University
Lymphoma
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in…
- Trial name
- NCT01390584
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma
- Trial name
- NCT03233347
- Testing
- Brentuximab Vedotin, Dacarbazine, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Academic and Community Cancer Research United
Leukemia, Myelodysplastic Syndrome
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
This is a pilot study which will be done in a small number of patients. The purpose of this study is to test the safety and benefit of giving a type of chemotherapy - cyclophosphamide - after the transplant to prevent graft…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02360111
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center